Posted On: 03/10/2016 4:32:39 PM
Post# of 72447
Agree.
Day one he stated his intention to provide marketable drug candidates and let someone else finish the approval process and/or buy the candidate and/or the company. Stated he would wait until B p3 before considering a partnership. The midterm data reports seems to be the most logical time for this to happen. If he waits until the end of p3, more valuable. Either works for me.
P p2 results also give us that opportunity for a near term partnership, as you know.
BOM, same thing.
K is on is on it's own track. Will have to wait for the p2 protocols and final p1 data.
With tomorrow's issue, nearing the end, going to the fullest extent of the timeframe, no problem for me. Makes it more difficult to contest and provides discouragement for anyone else to try this same sleaze tactic. If tossed early, cool.
The company's best direction is taking their drug candidates and using them for a variety of related issues, which they are doing. Add those partnership in and we're in for a nice ride.
Day one he stated his intention to provide marketable drug candidates and let someone else finish the approval process and/or buy the candidate and/or the company. Stated he would wait until B p3 before considering a partnership. The midterm data reports seems to be the most logical time for this to happen. If he waits until the end of p3, more valuable. Either works for me.
P p2 results also give us that opportunity for a near term partnership, as you know.
BOM, same thing.
K is on is on it's own track. Will have to wait for the p2 protocols and final p1 data.
With tomorrow's issue, nearing the end, going to the fullest extent of the timeframe, no problem for me. Makes it more difficult to contest and provides discouragement for anyone else to try this same sleaze tactic. If tossed early, cool.
The company's best direction is taking their drug candidates and using them for a variety of related issues, which they are doing. Add those partnership in and we're in for a nice ride.
(0)
(0)
